VANCOUVER, British Columbia – TheNewswire - October 18, 2023 – Treatment.com International Inc. (CSE:TRUE) (OTC:TREIF) (Frankfurt:939) (the “Company” or “Treatment”) is pleased to announce the appointment of Dr. Essam Hamza, MD to its Board of Directors and as Chief Executive Officer, effective October 17, 2023. Dr.Hamza will also join the Board on that date.
The appointment of Dr. Hamza follows a mandate to appoint a leader with a rare combination of extensive healthcare, technology and capital markets experience capable of leading the Company through the next phase of its growth. Dr.Hamza is a proven executer with a track record of successfully founding, leading and growing transformational healthcare companies. Most recently, he was the founder, a Director and CEO of CloudMD, a Vancouver based healthcare technology company.
Dr.Hamza is a seasoned and highly successful business visionary, steeped in medical and healthcare experience via his over 20 years as a medical doctor and a business builder as the founder of several healthcare companies including CloudMD Inc. From 2019 to 2022 at CloudMD, Dr. Hamza lead the company through tremendous growth, from a handful of employees and approximately $4M in annual sales in Canada, to hundreds of employees and customers across North American and over $100M in annual sales.
“Dr.Hamza is a proven leader and has a track record of success delivered through his extradonirary ability and understanding of healthcare, technology and entrepreneurship. I am excited for him to take the helm and lead the Company forward and create immense value for our shareholders,” said Dr. Kevin Peterson, Chairman.
Dr. Hamza stated “I’m very honoured and excited to join Treatment at this incredible inflection point for the company. I have been following story over the years and feel like the product is now ready for the next phase. The Company will now be focused on commercialization of its proprietary and best in class A.I. medical diagnostic tool. Over the next few months we will be updating the market on the progress of this commercialization and hope to announce some early wins.”
The Board would like to thank Dr.Kevin Peterson for his efforts during his time as interim CEO. Dr. Peterson will continue with Treatment as Chairman of the Board.
In connection with the management and executive appointments, the Company has granted 1,400,000 stock options exercisable at $0.25 for a five-year term and 1,150,000 restricted share units, valid for a three-year term to certain executive officers and consultants to the Company. The stock options and restricted share units are issued pursuant to the Company’s share compensation plans and are subject to vesting conditions.
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
(612) 788-8900
Cautionary Statements
This news release contains forward-looking statements that are based on Treatment.com’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
